Cresset Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cresset Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$3.56M	–	1836
2024 Q4	$3.56M	Sell	5,000 -2,300	-32%	-$1.93M	0.02%	412
2024 Q3	$7.67M	Sell	7,300 -800	-10%	-$890K	0.03%	368
2024 Q2	$8.51M	Buy	8,100 +3,700	+84%	+$3.59M	0.04%	319
2024 Q1	$4.23M	Sell	4,400 -400	-8%	-$380K	0.02%	410
2023 Q4	$4.22M	Buy	4,800 +1,400	+41%	+$1.15M	0.03%	382
2023 Q3	$2.8M	Sell	3,400 -246,600	-99%	-$194M	0.01%	448
2023 Q2	$180M	Buy	+250,000	New	+$193M	0.22%	33

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cresset Asset Management's REGN Position: Q1 2026 in Review

Cresset Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, selling an estimated $243K and leaving 2,537 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #562.

Cresset Asset Management first reported a position in REGN in Q4 2018 and has held it in 28 quarters since. The position peaked at $11M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Cresset Asset Management held 2,537 shares of Regeneron Pharmaceuticals worth $1.96M as of Q1 2026.
Cresset Asset Management sold 318 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $243K.
Regeneron Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q1 2026, its #562 holding.
Cresset Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
Cresset Asset Management's Regeneron Pharmaceuticals position peaked at $11M in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.